🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty

RecruitingNAAges 18 Years - 80 YearsAllMilitary Hospital of Tunis
NCT07869615 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Yes. For these two fields, I would enter the following in English, based on your study protocol. 1\. Brief Summary Copy and paste: This study aims to compare three thromboprophylaxis regimens in adults undergoing primary total knee arthroplasty: rivaroxaban 10 mg once daily, apixaban 2.5 mg twice daily, and low-molecular-weight heparin (LMWH) once daily. The study will assess venous blood flow in the lower limbs using Doppler ultrasound and determine whether blood flow differs between the three treatment groups. Participants will be randomly assigned to one of the three treatment groups and followed for 28 days after surgery. Doppler ultrasound examinations will be performed at baseline and on Days 7, 15, 21, and 28. Additional assessments will include rehabilitation progress, postoperative bleeding, suspected venous thromboembolism, cardiovascular complications, and other postoperati

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18 years or older undergoing elective primary unilateral total knee arthroplasty. * Able to provide informed consent. Exclusion Criteria: * Allergy or contraindication to the study medications. * Requirement for long-term therapeutic anticoagulation. * Requirement for antiplatelet therapy. * Pregnancy or lactation. * Active cancer or cancer treatment. * Documented previous venous thromboembolism in the target limb. * Hypercoagulable state. * BMI \>40 kg/m². * Severe inflammatory disease. * Age \>80 years. * Inability to comply with follow-up. * Incomplete data.
💊

What it tests

  • Apixaban
  • Rivaroxaban
  • Enoxaparin (LMWH)
📍

Where

1 site
Principal Military Hospital of Instruction of Tunis
Tunis, Tunisia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy